Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: EYPT

EyePoint Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for EYPT. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$-3.17

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-19 23:22 UTC.

What EyePoint Pharmaceuticals, Inc. does

EyePoint is a biopharmaceutical company developing treatments for retinal diseases using its proprietary Durasert E bioerodible drug delivery technology. The company's lead product candidate, DURAVYU, combines vorolanib, a selective tyrosine kinase inhibitor, with this delivery system and is being evaluated in Phase 3 clinical trials for wet age-related macular degeneration and diabetic macular edema. The company also has an additional pipeline program, EYP-2301, formulated in Durasert E to treat serious retinal diseases.

Summarized from EyePoint Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2025)$-3.17

Revenue, margins & earnings

FY2021: net loss $58M on revenue $37M$37MFY2021FY2022: net loss $102M on revenue $41M$41MFY2022FY2023: net loss $71M on revenue $46M$46MFY2023FY2024: net loss $131M on revenue $43M$43MFY2024FY2025: net loss $232M on revenue $31M$31MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-24
  • 2026-08-24Chief Financial OfficerGift64,953—
  • 2026-08-24Chief Financial OfficerOther-5,000—
  • 2026-08-24Chief Financial OfficerOther5,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does EyePoint Pharmaceuticals, Inc. do?

EyePoint is a biopharmaceutical company developing treatments for retinal diseases using its proprietary Durasert E bioerodible drug delivery technology.

When did EYPT last file with the SEC?

EyePoint Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-22. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-19 23:22 UTC. This page is also available as JSON at /api/data?ticker=EYPT and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for EYPT and 5,000+ tickers.

Create a free account — keep EYPT
For your agent
GET /api/data?ticker=EYPT

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt